A proof‐of‐concept, Phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide‐releasing anti‐inflammatory drug

BACKGROUND AND PURPOSE: ATB‐346 is a hydrogen sulfide (H(2)S)‐releasing anti‐inflammatory and analgesic drug. Animal studies demonstrated negligible gastrointestinal (GI) damage despite marked inhibition of COX activity and significant analgesic and anti‐inflammatory effects. In humans, ATB‐346 (250...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Pharmacol
Main Authors: Wallace, John L., Nagy, Peter, Feener, Troy D., Allain, Thibault, Ditrói, Tamás, Vaughan, David J., Muscara, Marcelo N., de Nucci, Gilberto, Buret, Andre G.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Themed Section: Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7024706/
https://ncbi.nlm.nih.gov/pubmed/30834513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.14641
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados